Compare AGM & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | NVAX |
|---|---|---|
| Founded | 1987 | 1987 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 1996 |
| Metric | AGM | NVAX |
|---|---|---|
| Price | $173.17 | $8.11 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | ★ $215.00 | $11.33 |
| AVG Volume (30 Days) | 68.2K | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $25.97 | N/A |
| Revenue Next Year | $12.21 | N/A |
| P/E Ratio | $9.95 | ★ $3.27 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $136.57 | $5.80 |
| 52 Week High | $210.64 | $11.85 |
| Indicator | AGM | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 69.69 | 40.20 |
| Support Level | $173.42 | $8.01 |
| Resistance Level | $179.02 | $8.45 |
| Average True Range (ATR) | 4.12 | 0.35 |
| MACD | 2.27 | 0.04 |
| Stochastic Oscillator | 84.93 | 29.30 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.